


Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936

### AMENDMENTS TO THE CLAIMS

Please replace all prior versions and listings of claims with the amended claims as follows:

1. (Currently amended) A compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

W<sup>1</sup> is nitrogen or CH, W<sup>2</sup> is nitrogen or C-(U)<sub>p</sub>R<sup>U</sup>, and W<sup>3</sup> is nitrogen or C-(V)<sub>q</sub>R<sup>V</sup>;

p and q are each independently 0 or 1;

R<sup>U</sup> and R<sup>V</sup> are each independently R or Ar<sup>1</sup>;


U and V are each independently a bond or a C<sub>1-6</sub> alkylidene chain, wherein up to two methylene units of the chain are optionally and independently replaced by CO, CO<sub>2</sub>, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, NRCO<sub>2</sub>, NRCONR, SO, SO<sub>2</sub>, NRSO<sub>2</sub>, SO<sub>2</sub>NR, NRSO<sub>2</sub>NR, O, S, or NR;

each occurrence of R is independently hydrogen or an optionally substituted C<sub>1</sub>-C<sub>4</sub> aliphatic, or two R bound to the same nitrogen atom are optionally taken together with the nitrogen atom to form a 3-7 membered saturated, partially unsaturated, or fully unsaturated ring having 0-2 additional heteroatoms independently selected from nitrogen, oxygen, or sulfur;

Ar<sup>1</sup> is a 5-7 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from

Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936

nitrogen, oxygen, or sulfur; wherein  $Ar^1$  is optionally substituted with  $m$  independent occurrences of  $Z-R^5$ ; wherein  $m$  is 0-5,  $Z$  is a bond or is a  $C_1-C_6$  alkylidene chain wherein up to two methylene units of  $Z$  are optionally replaced by CO,  $CO_2$ , COCO, CONR, OCONR, NRNR, NRNRCO, NRCO,  $NRCO_2$ , NRCONR, SO,  $SO_2$ ,  $NRSO_2$ ,  $SO_2NR$ ,  $NRSO_2NR$ , O, S, or NR; and each occurrence of  $R^5$  is independently hydrogen, an optionally substituted aliphatic, heteroaliphatic, aryl or heteroaryl group, halogen,  $NO_2$ , CN, OR, SR,  $N(R)_2$ ,  $NRCOR$ ,  $NRCON(R)_2$ ,  $NRCO_2R$ , COR,  $CO_2R$ , OCOR,  $CON(R)_2$ ,  $OCON(R)_2$ ,  $SOR$ ,  $SO_2R$ ,  $SO_2N(R)_2$ ,  $NRSO_2R$ ,  $NRSO_2N(R)_2$ ,  $COCOR$ , or  $COCH_2COR$ ;  $R^1$  and  $R^2$  are taken together and fused to ring B form a cyclic moiety selected from one of the following:



wherein each occurrence of  $R^X$  is independently hydrogen, QR, or  $Q_nAr^1$ ;  $n$  is zero or one; and  $Q$  is an optionally substituted  $C_{1-4}$  alkylidene chain wherein one methylene unit of  $Q$  is optionally replaced by CO,  $CO_2$ , COCO, CONR, OCONR, NRNR,

Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

NRNRCO, NRCO, NRCO<sub>2</sub>, NRCONR, SO, SO<sub>2</sub>, NRSO<sub>2</sub>, SO<sub>2</sub>NR, NRSO<sub>2</sub>NR, O, S,  
or NR;

R<sup>3</sup> is halogen, QR, Q<sub>n</sub>CN, Q<sub>n</sub>NO<sub>2</sub>, or Q<sub>n</sub>Ar<sup>1</sup>; and

R<sup>4</sup> is Ar<sup>1</sup>, or T-Ar<sup>1</sup>;

wherein T is a C<sub>1-2</sub> alkylidene chain wherein one methylene unit of T is optionally replaced by CO, CO<sub>2</sub>, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, NRCO<sub>2</sub>, NRCONR, SO, SO<sub>2</sub>, NRSO<sub>2</sub>, SO<sub>2</sub>NR, NRSO<sub>2</sub>NR, O, S, or NR.

2. (Original) The compound of claim 1, wherein R<sup>1</sup> and R<sup>2</sup> taken together represent heterocycle i and R<sup>x</sup> is hydrogen or optionally substituted C<sub>1-6</sub>aliphatic.
3. (Original) The compound of claim 1, wherein R<sup>x</sup> is hydrogen, methyl, ethyl, propyl, n-butyl, tert-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, C<sub>1-6</sub>alkyl substituted with N(R)<sub>2</sub>, or C<sub>1-6</sub>alkyl substituted with Ar<sup>1</sup>.
4. (Original) The compound of claim 1, wherein R<sup>x</sup> is hydrogen, methyl, or C<sub>1-2</sub>alkyl substituted with a group selected from optionally substituted phenyl, pyridyl, morpholino, piperidinyl, or piperazinyl.
5. (Original) The compound of claim 1, wherein R<sup>3</sup> is hydrogen, halogen, QR or QAr<sup>1</sup>, wherein Q is a C<sub>1-3</sub> alkylidene chain wherein one methylene unit of Q is optionally replaced by -O-, -S-, -NHCO-, or -NR-, and Ar<sup>1</sup> is an optionally substituted 5-6 membered saturated, partially unsaturated, or fully unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
6. (Original) The compound of claim 1, wherein R<sup>3</sup> is hydrogen, OH, OCH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, NHCOMe, NH<sub>2</sub>, NH(C<sub>1-4</sub> aliphatic), N(C<sub>1-4</sub> aliphatic)<sub>2</sub>, O(CH<sub>2</sub>)<sub>2</sub>morpholin-4-yl, O(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>, O(CH<sub>2</sub>)<sub>2</sub>NH(C<sub>1-4</sub> aliphatic), O(CH<sub>2</sub>)<sub>2</sub>N(C<sub>1-4</sub> aliphatic)<sub>2</sub>, Br, Cl, or F.
7. (Original) The compound of claim 1, wherein R<sup>3</sup> is hydrogen.

Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936


8. (Original) The compound of claim 1, wherein  $R^4$  is a 6-membered saturated, partially unsaturated, or aryl ring having 0-3 nitrogens, a 9-10 membered bicyclic aryl ring having 0-2 nitrogen atoms, or a 5 membered heteroaryl ring having 2-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein each ring is optionally substituted.
9. (Original) The compound of claim 1, wherein  $R^4$  is optionally substituted phenyl, cyclohexyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, thiazolyl, thiadiazolyl, pyrazolyl, isoxazolyl, indazolyl, or benzimidazolyl.
10. (Original) The compound of claim 1, wherein  $R^4$  is an optionally substituted phenyl group.
11. (Original) The compound of claim 8, wherein each occurrence of Z is independently a bond or a  $C_{1-4}$  alkylidene chain wherein one methylene unit of Z is optionally replaced by -O-, -S-, -SO<sub>2</sub>-, or -NH-; and each occurrence of  $R^5$  is independently hydrogen,  $C_{1-6}$  aliphatic, halogen, NO<sub>2</sub>, OR, N(R)<sub>2</sub>, or optionally substituted phenyl, pyridyl, or pyrimidinyl.
12. (Original) The compound of claim 8, wherein each occurrence of ZR<sup>5</sup> is independently Cl, F, Br, methyl, ethyl, t-butyl, isopropyl, cyclopropyl, nitro, CN, OMe, OEt, CF<sub>3</sub>, NH<sub>2</sub>, phenyl, benzyl, benzyloxy, OH, methylene dioxy, SO<sub>2</sub>NH<sub>2</sub>, CONH<sub>2</sub>, CO<sub>2</sub>Me, phenoxy, O-pyridinyl, SO<sub>2</sub>phenyl, nitrophenoxy, aminophenoxy, S-dimethylpyrimidine, NHphenyl, NH-methoxyphenyl, pyridinyl, aminophenyl, phenol, chloro-fluoro-phenyl, dimethylaminophenyl, CF<sub>3</sub>-phenyl, dimethylphenyl, chlorophenyl, fluorophenyl, methoxyphenoxy, chlorophenoxy, ethoxyphenoxy, and fluorophenoxy.

Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936


13. (Original) The compound of claim 1, wherein  $(U)_pR^U$  and  $(V)_qR^V$  are each independently hydrogen, halogen,  $NO_2$ , CN, OR, SR or  $N(R)_2$ , or  $C_{1-4}$ aliphatic optionally substituted with oxo, OR, SR,  $N(R)_2$ , halogen,  $NO_2$  or CN.

14. (Original) The compound of claim 1, wherein  $(U)_pR^U$  and  $(V)_qR^V$  are each independently hydrogen, Me, OH, or OMe.

15. (Original) The compound of claim 1, wherein  $W^1$  is N or CH and compounds have the structure of Formula Ia or Ib:




Ia




Ib

or a pharmaceutically acceptable salt thereof.

16. (Original) The compound of claim 1, wherein  $R^4$  is an optionally substituted phenyl group and compounds have the structure of Formula IIa or IIb:



IIa




IIb


Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936

or a pharmaceutically acceptable salt thereof.

17. (Original) The compound of claim 1, wherein  $R^3$  is hydrogen, and compounds have the general structure of Formula IIIa or IIIb:




IIIa




IIIb

or a pharmaceutically acceptable salt thereof.

18. (Original) The compound of claim 1, wherein  $R^3$  is hydrogen, and  $R^1$  and  $R^2$  taken together represent the heterocycle i and compounds have the general structure of Formula IVa or IVb:



IVa



IVb

or a pharmaceutically acceptable salt thereof.

19. (Original) The compound of any one of claims 15, 16, 17 or 18, wherein  
 i)  $R^1$  and  $R^2$  taken together represent the heterocycle i depicted above; where  $R^X$  is defined according to one of the following groups:  
 a. hydrogen or optionally substituted  $C_{1-6}$ aliphatic;

Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

- b. hydrogen, methyl, ethyl, propyl, n-butyl, tert-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, C<sub>1-6</sub>alkyl substituted with N(R)<sub>2</sub>, or C<sub>1-6</sub>alkyl substituted with Ar<sup>1</sup>; or
  - c. hydrogen, methyl, or C<sub>1-2</sub>alkyl substituted with a group selected from optionally substituted phenyl, pyridyl, morpholino, piperidinyl, or piperazinyl.
- ii) R<sup>3</sup> is defined according to one of the following groups:
- a. hydrogen, halogen, QR or QAr<sup>1</sup>, wherein Q is a C<sub>1-3</sub> alkylidene chain wherein one methylene unit of Q is optionally replaced by -O-, -S-, -NHCO-, or -NR-, and Ar<sup>1</sup> is an optionally substituted 5-6 membered saturated, partially unsaturated, or fully unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
  - b. hydrogen, OH, OCH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, NHCOMe, NH<sub>2</sub>, NH(C<sub>1-4</sub> aliphatic), N(C<sub>1-4</sub> aliphatic)<sub>2</sub>, O(CH<sub>2</sub>)<sub>2</sub>morpholin-4-yl, O(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>, O(CH<sub>2</sub>)<sub>2</sub>NH(C<sub>1-4</sub> aliphatic), O(CH<sub>2</sub>)<sub>2</sub>N(C<sub>1-4</sub> aliphatic)<sub>2</sub>, bromo, chloro, or fluoro; or
  - c. hydrogen;
- iii) R<sup>4</sup> is defined according to one of the following groups:
- a. a 6-membered saturated, partially unsaturated, or aryl ring having 0-3 nitrogens, a 9-10 membered bicyclic aryl ring having 0-2 nitrogens, or a 5 membered heteroaryl ring having 2-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein each ring is optionally substituted;
  - b. an optionally substituted ring selected from phenyl, cyclohexyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, thiazolyl, thiadiazolyl, pyrazolyl, isoxazolyl, indazolyl, or benzimidazolyl; or
  - c. an optionally substituted phenyl group;
- iv) W<sup>1</sup>, W<sup>2</sup> and W<sup>3</sup> are defined according to one of the following groups:
- a. W<sup>1</sup> is nitrogen or CH, W<sup>2</sup> is nitrogen or C-(U)<sub>p</sub>R<sup>U</sup>, and W<sup>3</sup> is nitrogen or C-(V)<sub>q</sub>R<sup>V</sup>;
  - b. W<sup>1</sup> is nitrogen or CH, W<sup>2</sup> is C-(U)<sub>p</sub>R<sup>U</sup>, and W<sup>3</sup> is C-(V)<sub>q</sub>R<sup>V</sup>; or

Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936

- c.  $W^1$  is nitrogen or CH and  $W^2$  and  $W^3$  are each CH; and
- v)  $(U)_pR^U$  and  $(V)_qR^V$  groups are defined according to one of the following groups:
- hydrogen, halogen,  $NO_2$ , CN, OR, SR or  $N(R)_2$ , or  $C_{1-4}$ aliphatic optionally substituted with oxo, OR, SR,  $N(R)_2$ , halogen,  $NO_2$  or CN;
  - hydrogen, Me, OH, OMe or  $N(R)_2$ ; or
  - both  $(U)_pR^U$  and  $(V)_qR^V$  are hydrogen.

20. (Original) The compound of claim 19, wherein each occurrence of Z is independently a bond or a  $C_{1-4}$  alkylidene chain wherein one methylene unit of Z is optionally replaced by -O-, -S-,  $-SO_2$ -, or -NH-; and each occurrence of  $R^5$  is independently hydrogen,  $C_{1-6}$  aliphatic, halogen,  $NO_2$ , OR,  $N(R)_2$ , or optionally substituted phenyl, pyridyl, and pyrimidinyl.


21. (Original) The compound of claim 19, wherein each occurrence of  $ZR^5$  is independently Cl, F, Br, methyl, ethyl, t-butyl, isopropyl, cyclopropyl, nitro, CN, OMe, OEt,  $CF_3$ ,  $NH_2$ , phenyl, benzyl, benzyloxy, OH, methylene dioxy,  $SO_2NH_2$ ,  $CONH_2$ ,  $CO_2Me$ , phenoxy, O-pyridinyl,  $SO_2$ phenyl, nitrophenoxy, aminophenoxy, S-dimethylpyrimidine, NHphenyl, NH-methoxyphenyl, pyridinyl, aminophenyl, phenol, chloro-fluoro-phenyl, dimethylaminophenyl,  $CF_3$ -phenyl, dimethylphenyl, chlorophenyl, fluorophenyl, methoxyphenoxy, chlorophenoxy, ethoxyphenoxy, or fluorophenoxy.

22. (Original) The compound of claim 1, having the formula IVa, wherein  $R^X$  is hydrogen or optionally substituted  $C_{1-6}$ aliphatic; m is 0, 1 or 2; and  $ZR^5$  is Cl, F, Br, methyl, ethyl, t-butyl, isopropyl, cyclopropyl, nitro, CN, OMe, OEt,  $CF_3$ ,  $NH_2$ , phenyl, benzyl, benzyloxy, OH, methylene dioxy,  $SO_2NH_2$ ,  $CONH_2$ ,  $CO_2Me$ , phenoxy, O-pyridinyl,  $SO_2$ phenyl, nitrophenoxy, aminophenoxy, S-dimethylpyrimidine, NHphenyl, NH-methoxyphenyl, pyridinyl, aminophenyl, phenol, chloro-fluoro-phenyl, dimethylaminophenyl,  $CF_3$ -phenyl, dimethylphenyl, chlorophenyl, fluorophenyl, methoxyphenoxy, chlorophenoxy, ethoxyphenoxy, or fluorophenoxy.




Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936


23. (Original) The compound of claim 1, selected from one of the following compounds:




IVa-1




IVa-2




IVa-3




IVa-4




IVa-5




IVa-6




IVa-7




IVa-8




IVa-9



IVa-10




IVa-11




IVa-12


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVa-13




IVa-14




IVa-15




IVa-16




IVa-17




IVa-18




IVa-19




IVa-20




IVa-21



IVa-22
















IVa-23




IVa-24


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

**IVa-25****IVa-26****IVa-27****IVa-28****IVa-29****IVa-30****IVa-31****IVa-32****IVa-33****IVa-34****IVa-35****IVa-36****IVa-37**


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVa-38




IVa-39




IVa-40




IVa-41




IVa-42




IVa-43




IVa-44




IVa-45




IVa-46




IVa-47



IVa-48




IVa-49




IVa-50


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVa-51




IVa-52




IVa-53




IVa-54




IVa-55




IVa-56




IVa-57




IVa-58



IVa-59














IVa-60




IVa-61


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

**IVa-62****IVa-63****IVa-64****IVa-65****IVa-66****IVa-67****IVa-68****IVa-69****IVa-70****IVa-71****IVa-72**


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-1




IVb-2




IVb-3




IVb-4




IVb-5




IVb-6




IVb-7




IVb-8




IVb-9



IVb-10




IVb-11




IVb-12


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-13




IVb-14




IVb-15




IVb-16




IVb-17




IVb-18




IVb-19




IVb-20




IVb-21



IVb-22




IVb-23




IVb-24




Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-25




IVb-26




IVb-27




IVb-28




IVb-29




IVb-30




IVb-31




IVb-32




IVb-33




IVb-34



IVb-35




IVb-36




IVb-37


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-38




IVb-39




IVb-40




IVb-41




IVb-42




IVb-43




IVb-44




IVb-45




IVb-46




IVb-47



IVb-48




IVb-49




IVb-50


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-51




IVb-52




IVb-53




IVb-54




IVb-55




IVb-56




IVb-57




IVb-58



IVb-59




IVb-60




IVb-61


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-62




IVb-63




IVb-64




IVb-65




IVb-66




IVb-67




IVb-68



IVb-69




IVb-70



IVb-71

or



IVb-72.

Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

24. (Original) A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

25. (Canceled)

26. (Currently amended) A method of inhibiting JAK-3 kinase activity in:

(a) a patient; or

(b) a biological sample;

which method comprises administering to said patient, or contacting said biological sample with a compound of claim 1 or a composition comprising said compound of claim 24.

27. (Currently amended) A method of treating or lessening the severity of a disease or disorder selected from an immune response, an autoimmune disease, a neurodegenerative disease, or a solid or hematologic malignancy comprising administering to a subject in need thereof a compound of claim 1 or a composition comprising said compound of claim 24.

28. (Original) The method of claim 27, wherein the disease or disorder is selected from an allergic or type I hypersensitivity reaction, asthma, transplant rejection, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis, multiple sclerosis, Familial amyotrophic lateral sclerosis (FALS), leukemia, or lymphoma.

29. (Original) The method of claim 28, comprising the further step of administering to said patient an additional therapeutic agent selected from a chemotherapeutic or anti-proliferative agent, a treatment for Alzheimer's Disease, a treatment for Parkinson's Disease, an agent for treating Multiple Sclerosis (MS), a treatment for asthma, an agent for treating schizophrenia, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular

Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

disease, an agent for treating destructive bone disorders, an agent for treating liver disease, an agent for treating a blood disorder, or an agent for treating an immunodeficiency disorder, wherein:

said additional therapeutic agent is appropriate for the disease being treated; and  
said additional therapeutic agent is administered together with said composition  
as a single dosage form or separately from said composition as part of a  
multiple dosage form.